12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pradaxa regulatory update

FDA reiterated its recommendation that Boehringer's Pradaxa dabigatran etexilate provides an important additional benefit when used as directed following its review of new information regarding the risk of serious bleeding in patients receiving the atrial fibrillation (AF) drug. The decision follows an investigation of insurance claims and administrative...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >